Summary:
A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of MIN-117 in Adult Patients with Major Depressive Disorder
Qualified Participants Must:
• Patients must be aged 18 to 65 years
Qualified Participants May Receive:
Compensation for time and travel